Cohance Lifesciences Reports Q2 Revenue of ₹4.77 Billion Versus ₹5.6 Billion YoY

Market snapshot: Cohance Lifesciences Limited reported Q2 revenue from operations of ₹477 crore (₹4.77 billion), reflecting a 14.82% YoY decline compared to ₹560 crore (₹5.6 billion) in the corresponding period last year. The revenue contraction highlights near-term top-line rebalancing across customer shipment cycles.

Data Snapshot

• Q2 Revenue from Operations: ₹477 crore versus ₹560 crore YoY, representing a decline of ≈14.82% YoY (derived: ₹477 cr vs ₹560 cr).
• Sequential Top-Line Growth: Q2 revenue of ₹477 crore recovered from ₹359.89 crore in Q1 FY27, recording a sequential expansion of ≈32.54% QoQ (derived: ₹477 cr vs ₹359.89 cr).

What's Changed

• Quarterly revenue adjusted to ₹477 crore from ₹560 crore YoY due to delivery timing across commercial innovator contracts.
• Sequential revenue accelerated by 32.54% over Q1 FY27 revenue of ₹359.89 crore, confirming a trough quarter in Q1.

Key Takeaways

• Cohance Lifesciences recorded Q2 revenue of ₹477 crore versus ₹560 crore YoY.
• Sequential growth demonstrates operational bounce-back from Q1 FY27 revenue lows.
• Pharma CDMO delivery timelines remain critical for sustained top-line acceleration.

SAHI Perspective

While Cohance Lifesciences recorded a 14.82% YoY decline in Q2 revenue to ₹477 crore, the 32.54% sequential expansion from Q1 FY27 indicates that supply-chain phasing is stabilizing. Market focus will center on customer order inflows and execution across late-stage development programs.

Market Implications

The year-on-year revenue contraction may weigh on immediate equity valuation metrics, but sequential top-line acceleration provides downside support. Clarity on CDMO order conversion will determine medium-term price trajectory.

Trading Signals

Market Bias: Neutral

Q2 revenue of ₹477 crore contracted 14.82% YoY from ₹560 crore, while expanding 32.54% sequentially over Q1 FY27 (₹359.89 crore). The mixed trajectory justifies a neutral bias pending confirmation of sustained margin stability.

Overweight: Pharma CDMO, Niche Technologies

Underweight: Specialty Chemicals

Trigger Factors:

• Management commentary on H2 contract execution during earnings conference call.
• Sustained quarterly expansion in consolidated gross and EBITDA margins.
• Progress in Phase III CDMO project pipeline transitions to commercial scale.

Time Horizon: Near-term (0-3 months)

Industry Context

The active pharmaceutical ingredient (API) and contract development and manufacturing organization (CDMO) industry continues to address global customer inventory destocking. Players with exposure to specialized modalities remain better positioned for structural growth.

Key Risks to Watch

• Customer shipment delays or contract re-phasing across active CDMO projects.
• Fluctuations in foreign exchange rates affecting international revenues.
• Raw material price volatility impacting gross margins.

Recent Developments

In October 2026, Cohance Lifesciences scheduled its Q2 FY27 investor conference call for 06 November 2026 following Board approval of financial results. In August 2026, the company posted Q1 FY27 revenue of ₹359.89 crore.

Closing Insight

Cohance Lifesciences' Q2 revenue indicates an operational turnaround from Q1 lows. Continued delivery on commercial programs will be pivotal for driving full-year growth momentum.

High Performance Trading with SAHI.